Treatment of an Adolescent With Chronic Myeloid Leukemia and the T315I Mutation With Ponatinib

被引：21
|
作者：
Nickel, Robert Sheppard [1 ]
Daves, Marla [1 ]
Keller, Frank [1 ]
机构：
[1] Emory Univ, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA
来源：
PEDIATRIC BLOOD & CANCER | 2015年 / 62卷 / 11期
关键词：
IMATINIB; GROWTH; CHILDREN;
D O I：
10.1002/pbc.25551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2050 / 2051
页数：2
相关论文
共 50 条
  • [21] A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients
    Wongboonma, Wanwisa
    Thongnoppakhun, Wanna
    Auewarakul, Chirayu U.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [22] A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation
    Nicolini, Franck-Emmanuel
    Huguet, Francoise
    Huynh, Lynn
    Xu, Churong
    Bouvier, Christophe
    Yocolly, Aurore
    Etienne, Gabriel
    CANCERS, 2023, 15 (16)
  • [23] Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT
    He, Jia-Bao
    Zhang, Xin
    Guo, Zi-Wen
    Liu, Miao-Miao
    Xu, Na
    Huang, Fen
    Fan, Zhi-Ping
    Xuan, Li
    Deng, Lan
    Lin, Shu-Hua
    Xu, Jun
    Sun, Jing
    Liu, Qi-Fa
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (04) : 1071 - 1077
  • [24] CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation
    Fang, Zhenghuan
    Jung, Kyung Hee
    Yan, Hong Hua
    Kim, Soo Jung
    Son, Mi Kwon
    Rumman, Marufa
    Lee, Hyunseung
    Kim, Ki Woon
    Yoo, Hye-Dong
    Hong, Soon-Sun
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (01) : 253 - 261
  • [25] Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report
    Cerveira, Nuno
    Ferreira, Rosa Branca
    Bizarro, Susana
    Correia, Cecilia
    Torres, Lurdes
    Lisboa, Susana
    Vieira, Joana
    Santos, Rui
    Campilho, Fernando
    Vaz, Carlos Pinho
    Leite, Luis
    Teixeira, Manuel R.
    Campos, Antonio
    BMC CANCER, 2018, 18
  • [26] Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation
    Takahashi, Naoto
    Miura, Masatomo
    Scott, Stuart A.
    Niioka, Takenori
    Sawada, Kenichi
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [27] Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors
    Xu, Peipei
    Guo, Dan
    Shao, Xiaoyan
    Peng, Miaoxin
    Chen, Bing
    ONCOTARGETS AND THERAPY, 2017, 10 : 4731 - 4738
  • [28] Validation of a Drosophila model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening
    Al Outa, Amani
    Abubaker, Dana
    Bazarbachi, Ali
    El Sabban, Marwan
    Shirinian, Margret
    Nosr, Rihab
    HAEMATOLOGICA, 2020, 105 (02) : 387 - 397
  • [29] Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
    Oaxaca, Derrick M.
    Yang-Reid, Sun Ah
    Ross, Jeremy A.
    Rodriguez, Georgialina
    Staniswalis, Joan G.
    Kirken, Robert A.
    TUMOR BIOLOGY, 2016, 37 (09) : 12643 - 12654
  • [30] Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors
    Manrique Arechavaleta, Gonzalo
    Scholl, Vanesa
    Perez, Veronica
    Bittencourt, Roberta
    Moellmann, Arthur
    Hassan, Rocio
    Seuanez, Hector N.
    Dobbin, Jane
    Martinez, Lem
    Renault, Ilana Zalcberg
    Uriarte, Rosario
    CLINICAL AND EXPERIMENTAL MEDICINE, 2011, 11 (01) : 55 - 59
12345